Explore
Home 
Literature 
Links 
Posts 
Molecules 
Blogs 
Zeitgeist 
Markup Help 
News 

Derek Lowes commentary on drug discovery and the pharma industry. An editorially independent blog from the publishers of Science Translational Medicine.

Most recent posts

Let’s get physical-organic. A big topic of research in recent years has been the properties of liquids and solids under boundary conditions. By that sweeping statement, I mean questions such as “When does a small cluster of metal atoms start to...
There’s been an interesting discussion about pharma R&D productivity and drug pricing on Twitter the last few days – here’s the starting point, from John Tucker. His thesis is that the hefty rate of inflation for medical services/hospitalization,...
Thanks to a comment on yesterday’s blog post, I was able to read this extraordinary tale, which comes to us courtesy of Prof. William Grover at UC Riverside’s Bioengineering department. Go check it out – you’ll learn of one Alireza Heidari,...

Most popular posts

Here’s a paper that will give many medicinal chemists a shiver of recognition. A group from Dundee reports a screening hit against the enzyme Ube2T, a ubiquitin-conjugating (E2) enzyme. For those outside the field, ubiquitin is indeed ubiquitous. It’s...
After years of work and untold amounts of money, Eli Lilly’s Alzheimer’s antibody, solanezumab, does not work. It does not help Alzheimer’s patients. No matter how many times you run the Phase III trials, or in which patient populations, they...
When you screen a collection of compounds against a drug target, you have to be ready to deal with the fact that some fraction – and maybe it’s a large fraction – of the hit compounds are not really hits. They’re false positives of one...

Latest posts linking here

The publication that I wanted to discuss was bought to my attention whilst reading Derek Lowe’s superb blog in the Pipeline. I would wholeheartedly recommend readers of this particular website to read the original blog discussion of the publication there....
A list of small, useful things (links):The latest from "All Things Metathesis" Philip Ball on what to look for in science in 2018I mean to write more about the Cronin 3D-printed flow reactors, but I'd like to associate myself with many of the critiques...
Hit-to-Lead optimisation is a crucial step in Drug Discovery. It implies the wise modification of hit molecules by following specific pharmacologic and pharmacokinetic parameters. Many strategies can be employed to tackle this challenge, one of them is bioisosterism....